Analysts' Actions: BIIB FSLR GOOG LNKD

TheStreet.com

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Biogen Idec BIIB was upgraded at Canaccord Genuity to buy. $187 price target. Expect an early launch for TEC, Canaccord Genuity said.

CoreSite Realty COR was upgraded to buy at TheStreet Ratings.

Darden DHI was upgraded at Bank of America/Merrill Lynch to neutral from underperform. $50 price target. Commitment to raise dividend trumps lower guidance, BofA/Merrill said.

DigitalGlobe DGI was upgraded to buy at TheStreet Ratings.

First Cash Financial Services FCFS was downgraded at Jefferies to hold from buy. Downgrading to hold on valuation, Jefferies said.

First Solar FSLR was downgraded at Robert Baird from outperform to neutral. $25 price target. Management has limited near-term visibility, Robert Baird said.

First Solar was downgraded at Bank of America/Merrill Lynch to underperform from buy. $25 price target. Solid results, disappointing outlook.

Google GOOG was upgraded at Bank of America/Merrill Lynch to buy. $920 price target. Expect the company to expand margins in the coming quarters, BofA/Merrill said.

GrafTech International GTI was downgraded at Goldman Sachs to sell from neutral. $5.50 price target. Worsening electrode oversupply structural issue, Goldman said.

Graftech was downgraded at J.P. Morgan to neutral. The company lacks earnings leverage, J.P. Morgan said.

Invensense INVN was downgraded at Robert Baird from outperform to neutral. Valuation call, based on a $13 price target, Baird said.

Lincoln National LNC was upgraded at Bank of America/Merrill Lynch. $34 price target. Company has the lowest multiple in the industry, BofA/Merrill said.

LinkedIn LNKD was initiated with a buy rating at Wunderlich. $195 price target. Company has a large competitive advantage and solid revenue visibility, Wunderlich said.

Allscripts MDRX was upgraded at Credit Suisse from neutral to outperform. $15 price target. New management can stabilize the business, Credit Suisse said.

Norwegian Cruise Line NCLH was initiated with a neutral rating at Goldman Sachs. $28 price target. Best in class, but valuation on an even keel, Goldman said.

Norwegian Cruise NCLH was initiated with an overweight rating at J.P. Morgan. $36 price target. Company can continue to increase price and yields, J.P. Morgan said.

Oceaneering OII was upgraded at Sterne Agee from neutral to buy. $75 price target. Company can generate robust earnings and cash flow over the next several years, Sterne Agee said.

Verisign VRSN was downgraded at Credit Suisse from outperform to neutral. $42.50 price target. Risk/reward is more balanced at current levels, Credit Suisse said.

Bio-Rad Laboratories BIO target was raised at Jefferies. Shares are now seen reaching $140. Strong fourth-quarter result, Jefferies said. Buy rating.

Darden Restaurants DRI numbers were lowered at Jefferies. Shares are now seen reaching $42. Estimates were also lowered on analyst meeting preannouncement, Jefferies said. Hold rating.

Expeditors International EXPD numbers were lowered at Jefferies. Shares are now seen reaching $44. Estimates were also lowered on earnings miss, Jefferies said. Buy rating.

Home Depot HD numbers were raised at UBS. Shares are now seen reaching $75. Estimates were also increased on strong execution, market share gains and good sector backdrop, UBS said. Buy rating.

Home Depot numbers were raised at Jefferies. Shares are now seen reaching $64. Estimates were also raised on share gains widening in the fourth quarter. Hold rating.

JPMorgan JPM estimates, price target were raised at BofA/Merrill. Shares are now seen reaching $55, according to Bank of America/Merrill Lynch. Estimates were also increased, as the company should see better net interest income and reserve releases, BofA/Merrill said. Buy rating.

Macy's M estimates were raised at UBS. Guidance points to accelerating FCF and expanding ROIC story. Neutral rating.

Priceline.com PCLN estimates, target were boosted at Benchmark. Shares are now seen reaching $800. Estimates were also increased, given accelerating international growth, Benchmark said. Buy rating.

Priceline.com target was raised at Jefferies. Shares are now seen reaching $820. Another solid quarter with some accelerating trends, Jefferies said. Buy rating.

Questcor Pharmaceuticals QCOR numbers were raised at Jefferies. Shares are now seen reaching $38. Estimates were also raised on strong fourth quarter with robust 2013 outlook, Jefferies said. Buy rating.

Vitamin Shoppe VSI numbers were reduced at Credit Suisse. Shares are now seen reaching $65. Estimates were also cut, as the company is facing cost headwinds, Credit Suisse said. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

View Comments (0)